Cargando…
Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in s...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463091/ https://www.ncbi.nlm.nih.gov/pubmed/28470951 http://dx.doi.org/10.1002/cam4.1080 |
_version_ | 1783242639724773376 |
---|---|
author | Posso, Margarita Corominas, Josep M. Serrano, Laia Román, Marta Torá‐Rocamora, Isabel Domingo, Laia Romero, Anabel Quintana, María Jesús Vernet‐Tomas, María Baré, Marisa Vidal, Carmen Sánchez, Mar Saladié, Francina Natal, Carmen Ferrer, Joana Servitja, Sònia Sala, María Castells, Xavier Burón, Andrea Rodríguez‐Arana, Ana Romero, Ana Vernet, Mar Andreu, Xavier Milà, Núria López‐Vilaró, Laura Fernández‐Somoano, Ana Galceran, Jaume Espinàs, Josep Alfons |
author_facet | Posso, Margarita Corominas, Josep M. Serrano, Laia Román, Marta Torá‐Rocamora, Isabel Domingo, Laia Romero, Anabel Quintana, María Jesús Vernet‐Tomas, María Baré, Marisa Vidal, Carmen Sánchez, Mar Saladié, Francina Natal, Carmen Ferrer, Joana Servitja, Sònia Sala, María Castells, Xavier Burón, Andrea Rodríguez‐Arana, Ana Romero, Ana Vernet, Mar Andreu, Xavier Milà, Núria López‐Vilaró, Laura Fernández‐Somoano, Ana Galceran, Jaume Espinàs, Josep Alfons |
author_sort | Posso, Margarita |
collection | PubMed |
description | Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case–control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow‐up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs’ specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with >90% of ER expression had a higher risk of breast cancer (OR = 2.63; 95% CI: 1.26–5.51) than women with ≤70% of ER expression. Similarly, women with >80% of PR expression had a higher risk of breast cancer (OR = 2.22; 95% CI: 1.15–4.27) than women with ≤40% of PR expression. Women with proliferative disease and ≥1% of Ki67 expression had a nonsignificantly increased risk of breast cancer (OR = 1.16; 95% CI: 0.46–2.90) than women with <1% of Ki67 expression. A high expression of ER and PR in BBD is associated with an increased risk of subsequent breast cancer. In proliferative disease, high Ki67 expression may also have an increased risk. This information is helpful to better characterize BBD and is one more step toward personalizing the clinical management of these women. |
format | Online Article Text |
id | pubmed-5463091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54630912017-06-09 Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study Posso, Margarita Corominas, Josep M. Serrano, Laia Román, Marta Torá‐Rocamora, Isabel Domingo, Laia Romero, Anabel Quintana, María Jesús Vernet‐Tomas, María Baré, Marisa Vidal, Carmen Sánchez, Mar Saladié, Francina Natal, Carmen Ferrer, Joana Servitja, Sònia Sala, María Castells, Xavier Burón, Andrea Rodríguez‐Arana, Ana Romero, Ana Vernet, Mar Andreu, Xavier Milà, Núria López‐Vilaró, Laura Fernández‐Somoano, Ana Galceran, Jaume Espinàs, Josep Alfons Cancer Med Cancer Prevention Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case–control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow‐up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs’ specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with >90% of ER expression had a higher risk of breast cancer (OR = 2.63; 95% CI: 1.26–5.51) than women with ≤70% of ER expression. Similarly, women with >80% of PR expression had a higher risk of breast cancer (OR = 2.22; 95% CI: 1.15–4.27) than women with ≤40% of PR expression. Women with proliferative disease and ≥1% of Ki67 expression had a nonsignificantly increased risk of breast cancer (OR = 1.16; 95% CI: 0.46–2.90) than women with <1% of Ki67 expression. A high expression of ER and PR in BBD is associated with an increased risk of subsequent breast cancer. In proliferative disease, high Ki67 expression may also have an increased risk. This information is helpful to better characterize BBD and is one more step toward personalizing the clinical management of these women. John Wiley and Sons Inc. 2017-05-04 /pmc/articles/PMC5463091/ /pubmed/28470951 http://dx.doi.org/10.1002/cam4.1080 Text en © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Posso, Margarita Corominas, Josep M. Serrano, Laia Román, Marta Torá‐Rocamora, Isabel Domingo, Laia Romero, Anabel Quintana, María Jesús Vernet‐Tomas, María Baré, Marisa Vidal, Carmen Sánchez, Mar Saladié, Francina Natal, Carmen Ferrer, Joana Servitja, Sònia Sala, María Castells, Xavier Burón, Andrea Rodríguez‐Arana, Ana Romero, Ana Vernet, Mar Andreu, Xavier Milà, Núria López‐Vilaró, Laura Fernández‐Somoano, Ana Galceran, Jaume Espinàs, Josep Alfons Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
title | Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
title_full | Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
title_fullStr | Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
title_full_unstemmed | Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
title_short | Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
title_sort | biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463091/ https://www.ncbi.nlm.nih.gov/pubmed/28470951 http://dx.doi.org/10.1002/cam4.1080 |
work_keys_str_mv | AT possomargarita biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT corominasjosepm biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT serranolaia biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT romanmarta biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT torarocamoraisabel biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT domingolaia biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT romeroanabel biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT quintanamariajesus biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT vernettomasmaria biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT baremarisa biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT vidalcarmen biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT sanchezmar biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT saladiefrancina biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT natalcarmen biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT ferrerjoana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT servitjasonia biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT salamaria biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT castellsxavier biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT buronandrea biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT rodriguezaranaana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT romeroana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT vernetmar biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT andreuxavier biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT milanuria biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT lopezvilarolaura biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT fernandezsomoanoana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT galceranjaume biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy AT espinasjosepalfons biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy |